Pilot evaluation of a HER2 testing in non-small-cell lung cancer

Katsuyuki Hotta; Hiroyuki Yanai; Kadoaki Ohashi; Kiichiro Ninomiya; Hiromi Nakashima; Hiroe Kayatani; Minoru Takata; Katsuyuki Kiura

doi:10.1136/jclinpath-2019-206204

Pilot evaluation of a HER2 testing in non-small-cell lung cancer

Katsuyuki Hotta, Hiroyuki Yanai, Kadoaki Ohashi, Kiichiro Ninomiya, Hiromi Nakashima, Hiroe Kayatani, Minoru Takata, Katsuyuki Kiura

University Hospital

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Aims HER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in non-small-cell lung cancer (NSCLC). Methods We evaluated the characteristics of HER2-positivity pattern in formalin-fixed paraffin-embedded samples using IHC and FISH in 15 patients enrolled in a larger prospective cohort study to survey a HER2-positive NSCLC. Results As for the immunostaining pattern, most specimens (79%) demonstrated incomplete or mixed-typed membranous immunoreactivity with heterogeneity, resembling that observed in gastric cancer rather than breast cancer. Concordance between IHC-positivity and FISH-positivity was 87.5% according to the criteria for breast cancer scoring system. On application of the gastric cancer scoring system to the examined tumours, the IHC score increased in the seven (43.8%) specimens, and the concordance between IHC positivity and FISH positivity rose to 93.8%. Conclusions In our pilot series, the pattern of IHC reactivity closely resembled that observed in gastric cancer rather than breast cancer. Trial registration number 000017003.

Original language	English
Pages (from-to)	353-357
Number of pages	5
Journal	Journal of Clinical Pathology
Volume	73
Issue number	6
DOIs	https://doi.org/10.1136/jclinpath-2019-206204
Publication status	Published - Jun 1 2020

Keywords

cancer
lung
staining

ASJC Scopus subject areas

Pathology and Forensic Medicine

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1136/jclinpath-2019-206204

Fingerprint Dive into the research topics of 'Pilot evaluation of a HER2 testing in non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this

@article{c8018cb3113b4375bcc98cff6b83ca24,

title = "Pilot evaluation of a HER2 testing in non-small-cell lung cancer",

abstract = "Aims HER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in non-small-cell lung cancer (NSCLC). Methods We evaluated the characteristics of HER2-positivity pattern in formalin-fixed paraffin-embedded samples using IHC and FISH in 15 patients enrolled in a larger prospective cohort study to survey a HER2-positive NSCLC. Results As for the immunostaining pattern, most specimens (79%) demonstrated incomplete or mixed-typed membranous immunoreactivity with heterogeneity, resembling that observed in gastric cancer rather than breast cancer. Concordance between IHC-positivity and FISH-positivity was 87.5% according to the criteria for breast cancer scoring system. On application of the gastric cancer scoring system to the examined tumours, the IHC score increased in the seven (43.8%) specimens, and the concordance between IHC positivity and FISH positivity rose to 93.8%. Conclusions In our pilot series, the pattern of IHC reactivity closely resembled that observed in gastric cancer rather than breast cancer. Trial registration number 000017003.",

keywords = "cancer, lung, staining",

author = "Katsuyuki Hotta and Hiroyuki Yanai and Kadoaki Ohashi and Kiichiro Ninomiya and Hiromi Nakashima and Hiroe Kayatani and Minoru Takata and Katsuyuki Kiura",

note = "Funding Information: Competing interests KH has received grants and personal fees from AstraZeneca, grants and personal fees from Eli Lilly, grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Ono Pharmaceutical, personal fees from Nippon Kayaku, personal fees from Taiho pharmaceutical, personal fees from Novartis, personal fees from Daiichi-Sankyo, personal fees from Kyorin, personal fees from Kyowa-Kirin, personal fees from Boehringer Ingelheim, grants from Astellas, and grants and personal fees from Chugai pharmaceutical outside the submitted work. KO has received a research grant from Novartis Pharmaceuticals Japan. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical and Sanofi-Aventis. Funding Information: Funding This research received a specific grant from the Japan Agency for Medical Research and Development, which is funded by the Japanese government. Publisher Copyright: {\textcopyright} Author(s) (or their employer(s)) 2020.",

year = "2020",

month = jun,

day = "1",

doi = "10.1136/jclinpath-2019-206204",

language = "English",

volume = "73",

pages = "353--357",

journal = "Molecular pathology : MP",

issn = "0021-9746",

publisher = "BMJ Publishing Group",

number = "6",

}

TY - JOUR

T1 - Pilot evaluation of a HER2 testing in non-small-cell lung cancer

AU - Hotta, Katsuyuki

AU - Yanai, Hiroyuki

AU - Ohashi, Kadoaki

AU - Ninomiya, Kiichiro

AU - Nakashima, Hiromi

AU - Kayatani, Hiroe

AU - Takata, Minoru

AU - Kiura, Katsuyuki

N1 - Funding Information: Competing interests KH has received grants and personal fees from AstraZeneca, grants and personal fees from Eli Lilly, grants and personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Ono Pharmaceutical, personal fees from Nippon Kayaku, personal fees from Taiho pharmaceutical, personal fees from Novartis, personal fees from Daiichi-Sankyo, personal fees from Kyorin, personal fees from Kyowa-Kirin, personal fees from Boehringer Ingelheim, grants from Astellas, and grants and personal fees from Chugai pharmaceutical outside the submitted work. KO has received a research grant from Novartis Pharmaceuticals Japan. KK has received honoraria from Eli Lilly Japan, Nihon Kayaku, AstraZeneca, Daiichi-Sankyo Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical and Sanofi-Aventis. Funding Information: Funding This research received a specific grant from the Japan Agency for Medical Research and Development, which is funded by the Japanese government. Publisher Copyright: © Author(s) (or their employer(s)) 2020.

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Aims HER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in non-small-cell lung cancer (NSCLC). Methods We evaluated the characteristics of HER2-positivity pattern in formalin-fixed paraffin-embedded samples using IHC and FISH in 15 patients enrolled in a larger prospective cohort study to survey a HER2-positive NSCLC. Results As for the immunostaining pattern, most specimens (79%) demonstrated incomplete or mixed-typed membranous immunoreactivity with heterogeneity, resembling that observed in gastric cancer rather than breast cancer. Concordance between IHC-positivity and FISH-positivity was 87.5% according to the criteria for breast cancer scoring system. On application of the gastric cancer scoring system to the examined tumours, the IHC score increased in the seven (43.8%) specimens, and the concordance between IHC positivity and FISH positivity rose to 93.8%. Conclusions In our pilot series, the pattern of IHC reactivity closely resembled that observed in gastric cancer rather than breast cancer. Trial registration number 000017003.

AB - Aims HER2-positivity pattern in the specimens of immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) has been hardly reported in non-small-cell lung cancer (NSCLC). Methods We evaluated the characteristics of HER2-positivity pattern in formalin-fixed paraffin-embedded samples using IHC and FISH in 15 patients enrolled in a larger prospective cohort study to survey a HER2-positive NSCLC. Results As for the immunostaining pattern, most specimens (79%) demonstrated incomplete or mixed-typed membranous immunoreactivity with heterogeneity, resembling that observed in gastric cancer rather than breast cancer. Concordance between IHC-positivity and FISH-positivity was 87.5% according to the criteria for breast cancer scoring system. On application of the gastric cancer scoring system to the examined tumours, the IHC score increased in the seven (43.8%) specimens, and the concordance between IHC positivity and FISH positivity rose to 93.8%. Conclusions In our pilot series, the pattern of IHC reactivity closely resembled that observed in gastric cancer rather than breast cancer. Trial registration number 000017003.

KW - cancer

KW - lung

KW - staining

UR - http://www.scopus.com/inward/record.url?scp=85075989817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075989817&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2019-206204

DO - 10.1136/jclinpath-2019-206204

M3 - Article

C2 - 31796633

AN - SCOPUS:85075989817

VL - 73

SP - 353

EP - 357

JO - Molecular pathology : MP

JF - Molecular pathology : MP

SN - 0021-9746

IS - 6

ER -

Pilot evaluation of a HER2 testing in non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this